Revolution Medicines Inc (OQ:RVMD)

Business Focus: Biotechnology & Medical Research

Apr 09, 2024 03:34 pm ET
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of a peer-reviewed research paper in Cancer Discovery. The scientific...
Apr 08, 2024 11:36 am ET
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of two peer-reviewed research papers in Nature. The first paper...
Apr 04, 2024 04:05 pm ET
Revolution Medicines to Participate in Upcoming Investor Conferences
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and...
Mar 28, 2024 04:05 pm ET
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the company will deliver multiple presentations at the upcoming American Association...
Feb 26, 2024 04:05 pm ET
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter and full year ended December 31, 2023, and...
Feb 20, 2024 04:05 pm ET
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2023 on Monday,...
Feb 01, 2024 04:05 pm ET
Revolution Medicines to Participate in Upcoming Investor Conferences
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a...
Jan 04, 2024 07:00 am ET
Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will...
Nov 09, 2023 09:10 am ET
Revolution Medicines Completes Acquisition of EQRx
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced it has closed its acquisition of EQRx, Inc. Through the acquisition, Revolution Medicines expects...
Nov 08, 2023 11:30 am ET
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. (Nasdaq: EQRX), announced that earlier today, at their respective special meetings, Revolution...
Nov 06, 2023 04:05 pm ET
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended September 30, 2023, and provided an update on corporate...
Nov 01, 2023 07:00 am ET
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and...
Oct 31, 2023 04:15 pm ET
Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the third quarter 2023 on Monday, November 6, 2023,...
Oct 22, 2023 02:30 am ET
Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced promising anti-tumor and safety data for RMC-6236, its RASMULTI(ON) Inhibitor, in patients with...
Oct 13, 2023 11:50 am ET
Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced encouraging preliminary clinical data for RMC-6236, its RASMULTI(ON) Inhibitor, and RMC-6291, its...
Oct 04, 2023 04:05 pm ET
Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company will present new clinical data for two of its RAS(ON) Inhibitors and other...
Sep 19, 2023 07:00 am ET
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-9805, an oral,...
Aug 17, 2023 04:05 pm ET
Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins
Selective Inhibitors Provides Preclinical Proof-of-Principle for Company's RAS Innovation Engine and Broad Pipeline REDWOOD CITY, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology...
Aug 10, 2023 11:17 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Capri Holdings Limited (NYSE – CPRI), Avid® (Nasdaq - AVID), EQRx, Inc. (Nasdaq - EQRX)
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Aug 08, 2023 04:05 pm ET
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2023, and provided an update on corporate...
Aug 06, 2023 08:50 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCU, NEWR, RVMD
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Sculptor Capital Management Inc....
Aug 05, 2023 08:13 pm ET
Lifshitz Law PLLC Announces Investigations of EQRX, RVMD, NEWR, and RETA
EQRx, Inc. (NASDAQ: EQRX) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of EQRX to Revolution Medicines, Inc. Under the terms of the proposed merger, EQRX shareholders will...
Aug 03, 2023 04:05 pm ET
Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2023 on Tuesday, August 8, 2023,...
Aug 01, 2023 09:20 am ET
RVMD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Revolution Medicines, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Revolution Medicines, Inc. (NASDAQ: RVMD) and EQRx, Inc. is fair to Revolution Medicines shareholders.
Aug 01, 2023 07:00 am ET
Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital
Revolution Medicines, Inc. (“Revolution Medicines” or the “Company”) (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. (“EQRx”) (Nasdaq: EQRX) today announced a definitive...
Jun 08, 2023 04:05 pm ET
Revolution Medicines to Participate in Upcoming Investor Conferences
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a...
May 24, 2023 04:05 pm ET
Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a...
May 08, 2023 04:02 pm ET
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2023, and provided an update on corporate...
May 01, 2023 04:05 pm ET
Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the first quarter 2023 on Monday, May 8, 2023,...
Apr 13, 2023 04:05 pm ET
Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be...
Apr 06, 2023 07:00 am ET
Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company and its collaborators will present preclinical data at the upcoming American...
Mar 07, 2023 04:02 pm ET
Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the closing of its underwritten public offering of 15,681,818 shares of common stock at a public...
Mar 02, 2023 09:15 pm ET
Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the pricing of its underwritten public offering of 13,636,364 shares of common stock at a public...
Mar 01, 2023 04:17 pm ET
Revolution Medicines Announces Commencement of Public Offering of Common Stock
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that it has commenced an underwritten public offering to sell up to $300 million of shares of its...
Feb 27, 2023 04:05 pm ET
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter and year ended December 31, 2022, and provided an update on...
Feb 21, 2023 04:05 pm ET
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2022 on Monday,...
Feb 02, 2023 07:00 am ET
Revolution Medicines to Participate in Upcoming Investor Conferences
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D.,...
Jan 03, 2023 07:00 am ET
Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will...
Dec 19, 2022 07:00 am ET
Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced publication of a manuscript in the Journal of Medicinal Chemistry that details the discovery...
Dec 07, 2022 04:05 pm ET
Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Sanofi has provided notice of termination of the parties’ global SHP2 development and...
Nov 09, 2022 04:05 pm ET
Revolution Medicines to Participate in Upcoming Investor Conferences
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D.,...
Nov 07, 2022 04:05 pm ET
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended September 30, 2022, and provided an update on corporate...
Nov 01, 2022 04:05 pm ET
Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the third quarter 2022 on Monday, November 7, 2022,...
Sep 22, 2022 07:00 am ET
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-6291, an oral,...
Sep 01, 2022 04:05 pm ET
Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced two senior management promotions, as well as the addition of a new member to its leadership team....
Aug 31, 2022 04:05 pm ET
Revolution Medicines to Participate in Upcoming Investor Conferences
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D.,...
Aug 09, 2022 04:02 pm ET
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2022, and provided an update on corporate...
Jul 28, 2022 04:02 pm ET
Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2022 on Tuesday, August 9, 2022,...
Jul 22, 2022 04:02 pm ET
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the closing of an underwritten public offering of 13,225,000 shares of common stock at a public...
Jul 19, 2022 10:41 pm ET
Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the pricing of its underwritten public offering of 11,500,000 shares of common stock at a public...
Jul 19, 2022 04:01 pm ET
Revolution Medicines Announces Commencement of Public Offering of Common Stock
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that it has commenced an underwritten public offering to sell up to $200 million of shares of its...
Jul 13, 2022 07:00 am ET
Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the appointment of Lorence Kim, M.D., to its board of directors. Dr. Kim has made significant...
Jun 28, 2022 07:00 am ET
Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-6236, the company’s...
Jun 09, 2022 04:02 pm ET
Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in the 43rd Annual Goldman Sachs Global Healthcare Conference....
May 09, 2022 04:02 pm ET
Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2022 and provided an update on corporate...
Apr 21, 2022 04:05 pm ET
Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the first quarter 2022 on Monday, May 9, 2022,...
Mar 09, 2022 07:30 am ET
Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company will make seven oral presentations at the upcoming American Association for Cancer...
Mar 01, 2022 04:05 pm ET
Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that the company will participate in the Cowen 42nd Annual Health Care Conference. Mark A....
Feb 28, 2022 04:05 pm ET
Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced its financial results for the fourth quarter and year ended December 31, 2021 and provided a...
Feb 22, 2022 04:05 pm ET
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February 28, 2022
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2021 on February...
Feb 03, 2022 07:30 am ET
Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that the company will participate in the Guggenheim Healthcare Talks 2022 Oncology...
Jan 11, 2022 02:15 pm ET
Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today reported progress across its pipeline of targeted therapeutics spanning its RAS(ON) Inhibitor and RAS...
Jan 04, 2022 07:30 am ET
Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman,...
Nov 24, 2021 07:30 am ET
Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate...
Nov 10, 2021 04:05 pm ET
Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced its financial results for the third quarter...
Nov 08, 2021 04:05 pm ET
Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate...
Nov 03, 2021 04:05 pm ET
Revolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that it will report financial...
Sep 30, 2021 07:30 am ET
Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that new preclinical data from...
Sep 15, 2021 07:30 am ET
Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate...
Sep 07, 2021 04:05 pm ET
Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D.,...
Aug 11, 2021 04:01 pm ET
Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced its financial results for the...
Aug 04, 2021 04:05 pm ET
Revolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that it will report financial...
Jun 24, 2021 04:05 pm ET
Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced the publication of an original scientific paper in...
Jun 10, 2021 07:30 am ET
Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that it will host a Science Talk webcast to highlight...
Jun 02, 2021 07:30 am ET
Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in the upcoming Goldman...
May 18, 2021 07:30 am ET
Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in the upcoming Cowen 2nd...
May 10, 2021 04:05 pm ET
Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced its financial results for the first...
May 03, 2021 07:05 am ET
Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today highlights the nomination of a slate of three individuals for...
Apr 21, 2021 07:00 am ET
Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced dosing of the first patient in a multicenter Phase...
Mar 11, 2021 04:05 pm ET
Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced the company will make six presentations at the...
Mar 09, 2021 07:30 am ET
Revolution Medicines to Participate in Upcoming Investor Conferences
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in two upcoming investor...
Mar 02, 2021 04:05 pm ET
Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced its financial results for the fourth quarter and...
Feb 18, 2021 07:30 am ET
Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in the upcoming Digital...
Feb 08, 2021 04:01 pm ET
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the closing of an underwritten public offering of 6,666,666 shares of common stock at a public offering price of $45.00 per share, before underwriting discounts and commissions. The shares of...
Feb 03, 2021 11:30 pm ET
Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock
Revolution Medicines, Inc. (Nasdaq: RVMD) today announced the pricing of its underwritten public offering of 5,797,101 shares of common stock at a public offering price of $45.00 per share, before underwriting discounts and commissions. All of the...
Feb 01, 2021 04:01 pm ET
Revolution Medicines Announces Proposed Public Offering of Common Stock
Revolution Medicines, Inc. (Nasdaq: RVMD) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common stock. All of the shares of common stock are being offered by Revolution Medicines. In addition,...
Jan 05, 2021 07:30 am ET
Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., chief executive officer...
Nov 12, 2020 07:30 am ET
Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced its financial results for the third quarter and...
Oct 24, 2020 09:45 am ET
Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today reported interim data from the company’s ongoing Phase 1b/2 clinical...
Oct 12, 2020 07:30 am ET
Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that interim data from the company’s ongoing Phase 1b/2...
Sep 16, 2020 09:00 am ET
Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today reported data demonstrating that its first-in-class...
Sep 09, 2020 07:30 am ET
Revolution Medicines to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., chief...
Sep 08, 2020 07:30 am ET
Revolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development Conference
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in the upcoming...
Aug 10, 2020 07:30 am ET
Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced its financial results for the second quarter and...
Jul 13, 2020 04:01 pm ET
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced the closing of an underwritten public...
Jul 08, 2020 10:48 pm ET
Revolution Medicines Announces Pricing of $156.0 Million Public Offering of Common Stock
Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at a public offering price of $26.00 per share, before underwriting discounts and commissions. All of the...
Jul 06, 2020 04:01 pm ET
Revolution Medicines Announces Proposed Public Offering of Common Stock
Revolution Medicines, Inc. (Nasdaq:RVMD) today announced that it has commenced an underwritten public offering of 5,500,000 shares of common stock. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution...
Jun 30, 2020 04:05 pm ET
Revolution Medicines Reports New Application of Tri-Complex Modality for “Undruggable” Protein Targets and Announces License to Ginkgo Bioworks to Explore Potential Use Against Novel Coronavirus
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced the publication of an original scientific paper in the Proceedings of the...
Jun 22, 2020 04:01 pm ET
Revolution Medicines Provides Research and Development Update for its Portfolio of Novel Targeted Cancer Therapies
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today provided a research and development (R&D) update regarding the company's innovative...
Jun 22, 2020 07:30 am ET
Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced dosing of the first patient in a multicenter Phase 1 clinical trial evaluating...
Jun 18, 2020 07:30 am ET
Revolution Medicines Appoints Eric T. Schmidt, Ph.D. and Peter Svennilson to its Board of Directors
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced the appointments of Eric T. Schmidt, Ph.D., and Peter Svennilson to its board...
Jun 09, 2020 07:30 am ET
Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced dosing of the first patient in a Phase 1b clinical trial evaluating the...
May 19, 2020 07:30 am ET
Revolution Medicines Announces Four Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced the company will make four presentations at the upcoming 2020 American...
May 14, 2020 04:05 pm ET
Revolution Medicines Reports First Quarter 2020 Financial Results and Continued Corporate Progress
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced its financial results for the first quarter ended March 31, 2020, and provided...
Apr 29, 2020 08:05 am ET
Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced the publication of an original scientific paper in Cancer Research, a journal...
Mar 18, 2020 07:30 am ET
Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced that the United States Patent and Trademark Office has issued U.S. Patent No....
Mar 09, 2020 07:30 am ET
New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced its intention to support the Netherlands Cancer Institute (NKI) on a...
Feb 18, 2020 04:01 pm ET
Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced the closing of its initial public offering...
Feb 12, 2020 07:39 pm ET
Revolution Medicines Announces Pricing of Initial Public Offering
Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the pricing of its initial public offering of 14,000,000 shares of common stock at a public offering price of $17.00 per share, before underwriting discounts and commissions. All of the...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.